BioAge Labs: Advancements in Aging and Financial Highlights
Promising oral NLRP3 inhibitor BGE-102 set for Phase 1 trials in late 2025 with results anticipated by year-end.
Pipeline enhanced through strategic options for a new APJ agonist and development of proprietary oral small molecules.
Significant progress in discovery platform, leveraging molecular profiling from over 17,000 samples within the renowned HUNT Biobank.
BioAge Labs, Inc. (NASDAQ: BIOA), a pioneering clinical-stage biotechnology company focused on developing therapeutic candidates that target the biology of aging, has recently shared significant business updates along with its financial results for the second quarter of 2025.
Kristen Fortney, the CEO and co-founder of BioAge, expressed pride in the company’s advancements, stating, "In Q2 2025, we accomplished pivotal milestones across our clinical pipeline and discovery initiatives. We successfully completed IND-enabling studies for our innovative NLRP3 inhibitor, BGE-102, positioning us to launch Phase 1 trials later this year, with preliminary single ascending dose (SAD) data expected by the end of the year. Furthermore, we have strengthened our APJ pipeline through the establishment of a partnership for potent APJ agonist antibodies and the filing of patent applications for promising small molecules. Additionally, our collaboration with the HUNT Biobank enables us to generate a vast amount of data that enriches our understanding of human longevity, reinforcing our mission to create transformative therapies for metabolic diseases."
Key Developments in Q2 2025
NLRP3 Inhibitor Program Progress
In a report shared in May 2025, BioAge announced that it wrapped up IND-enabling studies for BGE-102. This innovative oral NLRP3 inhibitor is being developed primarily for obesity treatment and has shown noteworthy weight loss in preclinical trials, both alone and combined with the GLP-1 receptor agonist, semaglutide. The company is poised to initiate a Phase 1 SAD/MAD clinical trial in the latter half of 2025, with initial SAC data expected before the year concludes.
Expansion of the APJ Agonist Pipeline
In June 2025, BioAge entered into an exclusive option agreement with JiKang Therapeutics (JiKang), which allows them to potentially in-license a novel APJ agonist nanobody, showing over tenfold greater effectiveness than natural APJ. Both BioAge and JiKang will collaborate to advance this nanobody to the early stages of IND-enabling studies, with BioAge holding an exclusive option for worldwide development and commercialization.
Moreover, in May, the company filed a provisional patent application in the U.S. for new classes of orally active APJ agonists demonstrating picomolar potency alongside favorable drug-like properties.
Expansion of the Discovery Platform
BioAge also announced a pivotal initiative in June 2025 aimed at profiling and analyzing samples collected from the HUNT Biobank in Norway. This collaboration with Age Labs AS will involve over 17,000 samples from more than 6,000 participants, generating millions of molecular data points that will help track the transition from health to disease over an entire lifespan. The findings from this partnership will be exclusively accessible for drug discovery purposes, enhancing BioAge's capacity to identify novel therapeutic targets.
Strategic Collaborations
In addition to the developments mentioned above, BioAge continued to advance its multi-year research collaboration with Novartis, announced in December 2024. This collaboration focuses on discovering groundbreaking therapeutic targets that lie at the intersection of aging biology and exercise physiology, exploring multiple targets with significant potential.
BioAge has also made strides in its collaboration with Lilly ExploR&D, which began in January 2025. This alliance is dedicated to developing therapeutic antibodies that target innovative metabolic aging pathways identified through BioAge’s unique discovery platform.
Financial Overview for Q2 2025
The financial results showed research and development expenses at $19.8 million for the quarter ending June 30, 2025, a substantial rise from the $10.5 million spent during the same quarter in 2024. This increase of $9.3 million primarily stemmed from heightened costs related to licensing, discovery, and developmental activities linked to the advanced APJ receptor programs. There was also a $3.0 million increase in expenses for the BGE-102 program attributed to detailed IND-enabling activities and drug-product manufacturing, although this was somewhat mitigated by a $1.7 million reduction in the costs associated with azelaprag, which was discontinued as of January 2025.
General and administrative expenses amounted to $7.3 million for the same quarter in 2025 compared to $4.8 million in 2024, an uptick attributed to rising personnel costs tied to stock-based compensation and increased legal fees.
The net loss reported was $21.6 million, or $0.60 per common share, a contrast to the net loss of $13.6 million, or $7.94 per common share, from the previous year’s quarter. As of June 30, 2025, BioAge maintained approximately $313.4 million in cash, cash equivalents, and marketable securities, sufficient to support operations through 2029 based on its current operating plan.
About BioAge Labs, Inc.
BioAge is on the cutting edge of biopharmaceutical advancements, striving to develop therapeutic solutions aimed at metabolic diseases through the science of human aging. Its flagship product, BGE-102, is a leading oral NLRP3 inhibitor that has showcased impressive efficacy in preclinical trials for obesity. BioAge also plans to initiate its Phase 1 SAD/MAD trial later this year, expecting the initial data by the year’s close. The company is actively pursuing long-acting injectables and oral small molecule APJ agonists for obesity treatment. Its additional preclinical initiatives leverage insights from its proprietary discovery platform rooted in human longevity data, targeting pivotal pathways linked to metabolic aging.
Frequently Asked Questions
What is the focus of BioAge Labs?
BioAge Labs specializes in developing therapeutic candidates aimed at combating metabolic diseases through innovative strategies targeting aging biology.
What milestones did BioAge Labs achieve in Q2 2025?
In Q2 2025, BioAge achieved key milestones including the completion of IND-enabling studies for BGE-102 and the establishment of significant strategic partnerships to enhance their drug pipeline.
What were BioAge Labs' financial results for Q2 2025?
The company reported a net loss of $21.6 million and research and development expenses of $19.8 million for the second quarter of 2025.
How is BioAge Labs utilizing data from the HUNT Biobank?
Data from the HUNT Biobank will be used to derive millions of molecular measurements to better understand the transition from health to disease, enhancing drug discovery efforts.
What are the prospects for BioAge Labs' products?
With ongoing clinical trials and strategic collaborations, BioAge Labs is well-positioned to bring transformative therapies to market, specifically targeting aging-related metabolic disorders.
